Correlation Between Transcode Therapeutics and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both Transcode Therapeutics and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Transcode Therapeutics and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Transcode Therapeutics and Dermata Therapeutics, you can compare the effects of market volatilities on Transcode Therapeutics and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Transcode Therapeutics with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Transcode Therapeutics and Dermata Therapeutics.

Diversification Opportunities for Transcode Therapeutics and Dermata Therapeutics

-0.04

Correlation Coefficient

Transcode Therapeutics  Dermata Therapeutics

Good diversification

The 3 months correlation between Transcode and Dermata is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Transcode Therapeutics and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Transcode Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Transcode Therapeutics are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Transcode Therapeutics i.e., Transcode Therapeutics and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Transcode Therapeutics and Dermata Therapeutics

Given the investment horizon of 90 days Transcode Therapeutics is expected to generate 1.7 times more return on investment than Dermata Therapeutics. However, Transcode Therapeutics is 1.7 times more volatile than Dermata Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Dermata Therapeutics is currently generating about -0.06 per unit of risk. If you would invest  1,000.00  in Transcode Therapeutics on May 10, 2025 and sell it today you would earn a total of  67.00  from holding Transcode Therapeutics or generate 6.7% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Transcode Therapeutics  vs.  Dermata Therapeutics

Transcode Therapeutics

Risk-Adjusted Performance

Soft

Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Dermata Therapeutics

Risk-Adjusted Performance

Weakest

Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Transcode Therapeutics and Dermata Therapeutics

The main advantage of trading using opposite Transcode Therapeutics and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Transcode Therapeutics position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind Transcode Therapeutics and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.